KYORIN Pharmaceutical (4569) Q3 2026 earnings summary

Executive summary

• Net sales for the nine months ended December 31, 2025, rose 3.6% year-over-year to ¥92,456 million.

• Operating profit increased 47.9% year-over-year to ¥4,609 million for the same period.

• Profit attributable to owners of parent grew 35.8% year-over-year to ¥5,097 million.

• Comprehensive income surged 149.9% year-over-year to ¥5,900 million.

Financial highlights

• Basic earnings per share for the nine months ended December 31, 2025, was ¥71.71, up from ¥42.46 a year earlier.

• Equity ratio as of December 31, 2025, was 71.5%.

• Total assets stood at ¥194,266 million, with net assets at ¥138,869 million as of December 31, 2025.

Outlook and guidance

• Full-year net sales forecast for the year ending March 31, 2026, is ¥127,000 million, a 2.4% decrease year-over-year.

• Operating profit is projected to decline 51.5% year-over-year to ¥6,100 million.

• Profit attributable to owners of parent is expected to fall 47.2% year-over-year to ¥4,800 million.

• Earnings per share for the full year are forecast at ¥83.55.